JAK2 L884P Mutation Confers Resistance To The Type II JAK2 Inhibitor NVP-BBT594 When Co-Occurring With JAK2 R683G But Not JAK2 V617F

被引：0
|
作者：
Kopp, Nadja
Van der Zwet, Jordy C.
Layer, Jacob
Weigert, Oliver
Vangrevelinghe, Eric
Yoda, Akinori
Radimerski, Thomas
Weinstock, David
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1429.1429
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1429
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Screening of JAK2 V617F mutation in multiple myeloma
    Fiorini, A.
    Farina, G.
    Reddiconto, G.
    Palladino, M.
    Rossi, E.
    Za, T.
    Laurenti, L.
    Giammarco, S.
    Chiusolo, P.
    Leone, G.
    Sica, S.
    LEUKEMIA, 2006, 20 (10) : 1912 - 1913
  • [22] THE JAK2 RS10974944 SNP, PART OF JAK2 46/1 HAPLOTYPE, STRONGLY PREDISPOSES TO JAK2 V617F POSITIVE MYELOPROLIFERATIVE NEOPLASMS
    Trifa, A.
    Cucuianu, A.
    Petrov, L.
    Urian, L.
    Dima, D.
    Militaru, M.
    Pop, I.
    Popp, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 598 - 598
  • [23] Prevalence of JAK2 exon 12 mutations among patients with polycythemia vera and without the JAK2 V617F mutation
    Fiorini, A.
    Za, T.
    Rossi, E.
    Ciminello, A.
    Chiusolo, P.
    Sica, S.
    Leone, G.
    De, Stefano, V
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 120 - 120
  • [24] Chronic Neutrophilic Leukemia with V617F JAK2 Mutation
    Gajendra, Smeeta
    Gupta, Ritu
    Chandgothia, Meenal
    Kumar, Lalit
    Gupta, Richa
    Chavan, Snehal Motilal
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2014, 30 (02) : 139 - 142
  • [25] Chronic Neutrophilic Leukemia with V617F JAK2 Mutation
    Smeeta Gajendra
    Ritu Gupta
    Meenal Chandgothia
    Lalit Kumar
    Richa Gupta
    Snehal Motilal Chavan
    Indian Journal of Hematology and Blood Transfusion, 2014, 30 : 139 - 142
  • [26] No evidence for JAK2 V617F mutation in colorectal cancer
    Herreros-Villanueva, M.
    Garcia-Giron, C.
    Er, T-K
    BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2010, 67 (04) : 220 - 222
  • [27] Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
    Komrokji, Rami S.
    Seymour, John F.
    Roberts, Andrew W.
    Wadleigh, Martha
    To, L. Bik
    Scherber, Robyn
    Turba, Elyce
    Dorr, Andrew
    Zhu, Joy
    Wang, Lixia
    Granston, Tanya
    Campbell, Mary S.
    Mesa, Ruben A.
    BLOOD, 2015, 125 (17) : 2649 - 2655
  • [28] JAK2 V617F Mutation Is Not Involved in Thromboembolism in IBD
    Karimi, Ouafae
    Crusius, J. Bart A.
    Coucoutsi, Constantina
    Heijmans, Roel
    Sambuelli, Alicia M.
    Pena, A. Salvador
    Koutroubakis, Ioannis E.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (11) : 1606 - 1607
  • [29] V617F mutation in JAK2 is associated idiopathic myelofibrosis
    Campbell, PJ
    Griesshammer, M
    Döhner, K
    Döhner, H
    Kusec, R
    Hasselbalch, HC
    Larsen, TS
    Pallisgaard, N
    Giraudier, S
    Le Bousse-Kerdilès, MC
    Desterke, C
    Guerton, B
    Dupriez, B
    Bordessoule, D
    Fenaux, P
    Kiladjian, JJ
    Viallard, JF
    Brière, J
    Harrison, CN
    Green, AR
    Reilly, JT
    BLOOD, 2006, 107 (05) : 2098 - 2100
  • [30] JAK2 (V617F) Mutation and Cerebral Venous Thrombosis
    Martinelli, Ida
    Passamonti, Serena Maria
    Biguzzi, Eugenia
    Franchi, Franca
    Gianniello, Francesca
    Bucciarelli, Paolo
    Pietra, Daniela
    Mannucci, Pier Mannuccio
    Cazzola, Mario
    BLOOD, 2011, 118 (21) : 1433 - 1433
12345